HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Systemic VHL gene functions and the VHL diseaseEpimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesBelinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective reviewCombating the epigenome: epigenetic drugs against non-Hodgkin's lymphomaKATs in cancer: functions and therapiesAurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivoGene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups.Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy.Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.Inhibiting DNA Methylation by 5-Aza-2'-deoxycytidine ameliorates atherosclerosis through suppressing macrophage inflammation.DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor responseTargeting Histone Deacetylases in Diseases: Where Are We?Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor TherapyUse of class I histone deacetylase inhibitor romidepsin in combination regimensCombinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.Decitabine in the treatment of acute myeloid leukemia in elderly patients.A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.Role of p53 family members p73 and p63 in human hematological malignancies.HDAC inhibitor-based therapies: can we interpret the code?Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.Transcriptional Selectivity of Epigenetic Therapy in Cancer.Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Factors affecting the persistence of drug-induced reprogramming of the cancer methylome.Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.Method to Assess Interactivity of Drugs with Nonparallel Concentration-Effect Relationships.The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma.Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia.DNA Hypomethylating Drugs in Cancer Therapy.SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.
P2860
Q24597424-F67B774C-7D20-44E1-A1FE-7EAAB5F9080FQ24605882-58A713BD-5F23-480D-932A-707D90E275E8Q26744080-04D71646-1085-4B70-8A96-CA7BF8CA653AQ26796449-7F9F0F90-FDFB-4D8C-BD3C-E240442BA450Q26851166-81316F94-6BD3-47EE-A7B1-F2B7B4F1A92AQ26859355-09F97BFE-05F3-4EE3-B8C2-80DC940A0B53Q27346432-AE5C46B1-B54F-4745-95AA-4EFE8C176068Q28263221-C5D9377D-5A69-4E79-97D5-E19A4400549DQ33901284-6B00B129-5B58-4910-B4ED-1CC3E780B2C2Q33913937-1DA79E35-9E41-4C3C-B76B-A8C22F7981C9Q34345218-82148356-954A-40F9-A43C-4B0977FBB2B3Q34551679-588E4D21-6B61-4106-9F3F-8DF37D321106Q35561291-FF377B37-CA2F-4C26-B889-B88C7ED390BCQ35741605-B89A6460-296A-40D0-9434-B8D5CBBFE6C4Q35821728-5095314F-EE23-4BAE-A118-5809F397995FQ36015007-DF28CAC2-6301-4D5A-9E38-72C6CDB51EF0Q36172596-2E21D165-DA53-4527-B8B7-2DF98A5E7584Q36882942-A562D59C-C7AB-440F-BD10-45A46030E94CQ37107439-CC5CE05B-AF50-41DF-B6C9-25AF25648084Q37117964-ADD493F7-D61C-4126-9519-6232EAC99F54Q37192391-7A1EEA26-06BC-4021-9659-7BF78588B5F9Q37568244-27C40FB0-008E-401E-8522-389777AB5EF4Q37589239-DD054B72-691D-4462-B754-6959A594FC48Q38002122-3790774D-365D-4B6B-8AEB-3B503A5A09B2Q38058971-B7CD1F64-A17E-49A7-BB4C-36636C313A2BQ38542620-2CC685A5-650F-44A1-9C7D-44300CAF3B6DQ38725415-C196A07C-2709-454F-B319-E387237A5A0EQ38729313-2CEF0B9A-8D76-47C8-8DE6-FFAEC31F2DA9Q38735639-A1012E48-0AA6-4C87-BA1B-FDD6956680CCQ38765451-2286EDB4-DBDF-40C2-B483-D1F985ECDBA8Q38777889-CE5BB818-16F3-4610-8737-B9A697A022E7Q38790957-B237A63F-6CF0-4572-B995-FC976284D78CQ38819975-A8A5C57F-4E2D-4CCA-BA3B-2551C1F839AEQ38866872-ED392BB0-FFB4-4AB3-89B1-C802801D232DQ38888975-C512127E-0105-4E0D-ADDB-968D54DED5E0Q38906418-CCA82CFE-0682-4A49-B83A-DF110BE21875Q38973962-D368DE2C-B0F4-4337-A9EF-31E78D7BD094Q38979940-0C96E4DD-840E-4BA4-8C23-8C35C4C20173Q39011822-AD7EE4BA-7AD5-49E9-A820-03D23429D2F5Q39091822-BFDE9F3A-C153-4805-912F-F736A75E2EF8
P2860
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL
@ast
HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL
@en
type
label
HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL
@ast
HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL
@en
prefLabel
HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL
@ast
HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL
@en
P2093
P2860
P1433
P1476
HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL
@en
P2093
Alexis M Temkin
Benjamin Tycko
Enrica Marchi
Govind Bhagat
Jennifer Amengual
Luigi Scotto
Matko Kalac
Netha Ulahannan
Owen A O'Connor
Samir Parekh
P2860
P304
P356
10.1182/BLOOD-2011-02-336891
P407
P577
2011-07-19T00:00:00Z